LATS 是一类高度保守的丝氨酸/苏氨酸蛋白激酶,属于 AGC 激酶家族,主要包括 LATS1 和 LATS2 两个同源成员。两者在功能上高度重叠,广泛参与肿瘤抑制、细胞周期检查点、凋亡、迁移及器官大小调控等过程。
LATS 是 Hippo 通路中直接作用于 YAP 的激酶,它通过磷酸化 YAP 的 Ser127 和 Ser381 位点,分别实现了“胞质滞留”和“引物介导的蛋白降解”这两种协调一致的机制,从而精确且强效地抑制 YAP 的致癌活性。
LATS is a type of highly conserved serine/threonine protein kinase, belonging to the AGC kinase family. It mainly consists of two homologous members, LATS1 and LATS2. The two have a high degree of functional overlap and are widely involved in processes such as tumor suppression, cell cycle checkpoints, apoptosis, migration, and organ size regulation.
LATS is an enzyme in the Hippo pathway that directly acts on YAP. It achieves two coordinated mechanisms, namely "cytoplasmic retention" and "primer-mediated protein degradation", by phosphorylating the Ser127 and Ser381 sites of YAP. As a result, it precisely and powerfully inhibits the oncogenic activity of YAP.
DDO-4033 是一种 SPOP 抑制剂(IC50 = 16.9 μM,Kd = 15.1 μM),可阻碍透明细胞肾细胞癌 (ccRCC) 细胞系的恶性迁移、侵袭和增殖,并通过破坏 SPOP 对底物 LATS1 的募集、抑制其多泛素化和随后的降解来上调 LATS1 的表达,具有良好的抗肿瘤活性,可用于肾细胞癌研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号